 Rhabdomyosarcoma
"Rhabdomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Descriptor ID |
D012208
|
| MeSH Number(s) |
C04.557.450.590.550.660 C04.557.450.795.550.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rhabdomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Rhabdomyosarcoma".
This graph shows the total number of publications written about "Rhabdomyosarcoma" by people in this website by year, and whether "Rhabdomyosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 3 | 0 | 3 | | 2014 | 1 | 1 | 2 | | 2015 | 0 | 1 | 1 | | 2017 | 3 | 2 | 5 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 1 | 2 | | 2020 | 3 | 2 | 5 | | 2021 | 4 | 0 | 4 | | 2022 | 5 | 0 | 5 | | 2023 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Rhabdomyosarcoma" by people in Profiles.
-
Schloemer NJ, Xue W, Qumseya A, Luo LY, Hiniker SM, Lautz TB, Rhee DS, Arnold MA, Venkatramani R. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2023 Dec; 70(12):e30701.
-
M?ller JA, Delank KS, Laudner K, Wittenberg I, Zeh A, Vordermark D, Medenwald D. Clinical characteristics of sarcoma patients: a population-based data analysis from a German clinical cancer registry. J Cancer Res Clin Oncol. 2023 Dec; 149(19):17051-17069.
-
McLean-Thomas L, Gao D, Trenbeath Z, Cost CR, Milgrom SA. Equivocal end-of-therapy imaging findings do not predict a higher risk of local relapse after definitive radiotherapy in pediatric Ewing sarcoma and rhabdomyosarcoma. Pediatr Blood Cancer. 2023 05; 70(5):e29989.
-
Castle AMR, Empringham B, Pinto LM, Villani A, Kanwar N, Abbott LS, Sawyer SL. Rhabdomyosarcoma as the first presentation in Neurofibromatosis Type 1: case series and review of the literature. Pediatr Hematol Oncol. 2023; 40(5):506-515.
-
Patel AG, Chen X, Huang X, Clay MR, Komorova N, Krasin MJ, Pappo A, Tillman H, Orr BA, McEvoy J, Gordon B, Blankenship K, Reilly C, Zhou X, Norrie JL, Karlstrom A, Yu J, Wodarz D, Stewart E, Dyer MA. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Dev Cell. 2022 05 23; 57(10):1226-1240.e8.
-
Halstead NV, Mikkilineni N, Cost CR, Cost NG. Aggressive Multimodality Therapy for a Urachal Rhabdomyosarcoma. Urology. 2022 07; 165:e20-e24.
-
Whittle S, Venkatramani R, Sch?nstein A, Pack SD, Alaggio R, Vokuhl C, Rudzinski ER, Wulf AL, Zin A, Gruver JR, Arnold MA, Merks JHM, Hettmer S, Koscielniak E, Barr FG, Hawkins DS, Bisogno G, Sparber-Sauer M. Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. Eur J Cancer. 2022 06; 168:56-64.
-
Garrido C, Letona T, Godoy S, Antill?n F, Valverde P, Luna-Finemann S, Rodr?guez-Galindo C, Fuentes S, Arambu I, Calder?n P, Ortiz R, Montero M, Blanco J, Valsecchi MG, Ferrari A. Rhabdomyosarcoma in low- and middle-income countries: A report from the Asociacion de Hemato-oncolog?a Pediatrica de Centro Am?rica (AHOPCA). Pediatr Blood Cancer. 2023 Aug; 70(8):e29669.
-
Davies OMT, Bruckner AL, McCalmont T, Mascarenhas L, Oza V, Williams ML, Wine-Lee L, Shern JF, Siegel DH. Cutaneous mosaic RASopathies associated with rhabdomyosarcoma. Pediatr Blood Cancer. 2022 05; 69(5):e29639.
-
Hsu JY, Danis EP, Nance S, O'Brien JH, Gustafson AL, Wessells VM, Goodspeed AE, Talbot JC, Amacher SL, Jedlicka P, Black JC, Costello JC, Durbin AD, Artinger KB, Ford HL. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state. Cell Rep. 2022 02 01; 38(5):110323.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|